InfuSystem provides 2024 guidance: revenue ~$134.2M, adjusted EBITDA ~$26.5M

InfuSystem Holdings, Inc

TTM revenue through 9/30/24 $132.8M; estimated FY2024 revenue $134.2M (high single-digit growth).
Adjusted EBITDA estimated at $26.5M for FY2024, margin ~19.7% (high teens % of revenue).
Net leverage ratio 1.15x; debt/equity 0.90x; $20M stock repurchase program available.
Capital allocation prioritized: organic growth, debt reduction (target leverage 1.5x-2.0x), and opportunistic buybacks.
Patient Services gross margin improved to 66.0% TTM; Device Solutions gross margin 31.3% TTM.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.